Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1551-1557

  Jin, Lei ^a,b   Sturgis, Erich M ^a   Zhang, Yang ^a,c   Huang, Zhigang ^a,c   Wei, Peng ^d   Guo, Wei ^a,c   Wang, Zhongqiu ^a,e   Wei, Qingyi ^a   Song, Xicheng ^a,f   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^f YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CONFIDENCE INTERVALS; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENES, P53; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 84880298525     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt096     Document Type: Article

References (39)

1. Curado, M.P. et al. (2009) Recent changes in the epidemiology of head and neck cancer. Curr. Opin. Oncol., 21, 194-200.
2. Di Martino, E. et al. (2002) Survival in second primary malignancies of patients with head and neck cancer. J. Laryngol. Otol., 116, 831-838.
3. Manikantan, K. et al. (2011) Current concepts of surveillance and its significance in head and neck cancer. Ann. R. Coll. Surg. Engl., 93, 576-582.
4. Sturgis, E.M. et al. (1995) Second primary malignancies in the head and neck cancer patient. Ann. Otol. Rhinol. Laryngol., 104, 946-954.
5. Dahlstrom, K.R. et al. (2008) Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck, 30, 75-84.
6. Hymowitz, N. (2011) Smoking and cancer: a review of public health and clinical implications. J. Natl Med. Assoc., 103, 695-700.
7. Leemans, C.R. et al. (2011) The molecular biology of head and neck cancer. Nat. Rev. Cancer, 11, 9-22.
8. Leon, X. et al. (2009) Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. Cancer Causes Control, 20, 645-652.
9. Hang, B. (2010) Formation and repair of tobacco carcinogen-derived bulky DNA adducts. J. Nucleic Acids, 2010, 709521.
10. Moktar, A. et al. (2011) Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int. J. Oncol., 39, 941-947.
11. Sturgis, E.M. et al. (2000) XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis, 21, 2219-2223.
12. Taioli, E. (2008) Gene-environment interaction in tobacco-related cancers. Carcinogenesis, 29, 1467-1474.
13. Pfeifer, G.P. et al. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21, 7435-7451.
14. Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15-16.
15. Harris, S.L. et al. (2005) The p53 pathway: positive and negative feedback loops. Oncogene, 24, 2899-2908.
16. Hoffmann, T.K. et al. (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol., 44, 1100-1109.
17. Li, F. et al. (2010) Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer, 116, 2350-2359.
18. Li, F. et al. (2009) p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. Int. J. Cancer, 125, 2660-2665.
19. Zhang, Y. et al. (2011) p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Cancer, 117, 1227-1235.
20. Yu, H. et al. (2011) Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol. Carcinog., 50, 697-706.
21. Yu, H. et al. (2011) Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet. Genomics, 21, 388-396.
22. Warren, S. et al. (1932) Multiple primary malignant tumors: a survey of the literature and statistical study. Am. J. Cancer, 51, 1358.
23. Klein, J.P. et al. (2003) Survival Analysis: Techniques for Censored and Truncated Data. 2nd edn. Springer, New York.
24. Collett, D. (2003) Modelling Survival Data in Medical Research. 2nd edn. Chapman & Hall, Bristol, UK.
25. Cox, DR. (1972) Regression models and life tables. J. R. Stat. Soc. B, 34, 187-220.
26. Liu, F. et al. (2011) p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies. Mutagenesis, 26, 573-581.
27. Sun, T. et al. (2010) Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin. Cancer Res., 16, 5244-5251.
28. Wang, L. et al. (2012) Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol. Biol. Rep., 39, 1731-1738.
29. Zhang, Y. et al. (2012) Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck. Cancer, 118, 485-492.
30. Weber, A. et al. (2002) INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch., 441, 133-142.
31. Xia, L. et al. (2004) p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF. Cancer Res., 64, 221-228.
32. Marine, J.C. (2011) MDM2 and MDMX in cancer and development. Curr. Top. Dev. Biol., 94, 45-75.
33. Kotnis, A. et al. (2012) Multiple pathway-based genetic variations associated with tobacco related multiple primary neoplasms. PLoS ONE, 7, e30013.
34. Wu, X. et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev. Res. (Phila.), 2, 617-624.
35. Morris, L.G. et al. (2011) Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Cancer Causes Control, 22, 671-679.
36. Morris, L.G. et al. (2011) Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirusassociated oropharyngeal cancer. J. Clin. Oncol., 29, 739-746.
37. Almadori, G. et al. (2004) Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review. Eur. J. Cancer, 40, 2383-2388.
38. Slaughter, D.P. et al. (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 6, 963-968.
39. Muto, M. et al. (2002) Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer. Carcinogenesis, 23, 1759-1765.